- recruitingTherapeutic exploratory (Phase II)
Phase 2, multicenter, randomized, open-label, controlled, 2-arm cross-over study to evaluate the clinical efficacy and safety of a renin inhibitor, aliskiren, compared to an angiotensin converting enzyme inhibitor, enalapril, in children and adults with C3 glomerulopathy
This study is looking at two medicines, aliskiren and enalapril, for people with a rare kidney disease called C3 glomerulopathy. We want to see how well they work to protect your kidneys and if they are safe. It involves taking both medicines at different times.
Sweden - active not recruitingPHASE3
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
This study looks at the long-term effects of a medicine called pegcetacoplan for kidney conditions like C3 Glomerulopathy (C3G) and IC-MPGN. It's for people who were in a previous study and seemed to benefit from the treatment.
United States · Argentina · Australia - recruitingPHASE2
Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN
This study is testing a new drug, OMS906, for adults with two rare kidney diseases: C3 Glomerulopathy (C3G) and Idiopathic Immune Complex-Mediated Glomerulonephritis (ICGN). We want to see how safe it is and if it helps improve their condition.
Lithuania · New Zealand · Poland - recruiting
National Registry of Rare Kidney Diseases
This registry is collecting information from people with rare kidney diseases across the UK. It aims to improve understanding, create better care guidelines, and help develop new treatments for these conditions. If you have a rare kidney disease, your information could help.
United Kingdom - recruitingPHASE3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
This study looks at a new medicine called iptacopan for rare kidney diseases (C3G and IC-MPGN). It checks how well it works and if it's safe over a long time. This is for people who were already in earlier studies of this medicine.
United States · Argentina · Brazil